07:00 , Aug 18, 2014 |  BioCentury  |  Strategy

Breathing room

AstraZeneca plc's acquisition of Almirall S.A.'s respiratory assets should buy the pharma time while its respiratory pipeline matures. The deal not only gives AstraZeneca a faster route to market in the COPD combination therapy race...